Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, Hirokazu Muraoka, Akihiro Sato, Kumi Chubachi, Atsushi Yanai, Hiroko Arioka, Yuki Uehara, Genei Ihara, Yasuyuki Kato, Naoki Yanagisawa, Akihiro Ueda, Hideaki Kato, Hideaki Oka, Yusuke Nishida, Yuki Nidaira, Takahiro Asami, Torahiko Jinta, Akira Nakamura, Kunihiro Oba, Daisuke Taniyama, Kei Yamamoto, Katsushi Tanaka, Kankuro Ueshima, Tetsuji Fuwa, Ashley Stucky, Tadaki Suzuki, Chris Smith, Martin Hibberd, Koya Ariyoshi, Motoi Suzuki
Open Forum Infectious Diseases, May 3, 2023
Abstract
In this multi-center prospective test-negative case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65% and 76%) and moderate compared to monovalent vaccines administered over half a year before (46% combined).